**Immunology and Immune Checkpoints**

|  |  |
| --- | --- |
| Resource | Address |
| Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. *Clin Cancer Res.* 2015;21:687-692. | [www.ncbi.nlm.nih.gov/pmc/articles/PMC4334715/pdf/nihms649710.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334715/pdf/nihms649710.pdf) |
| Chen DS, Irving BA, Hodi FS. Molecular pathways: Next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. *Clin Cancer Res.* 2012;18:6580-6587. | <https://clincancerres.aacrjournals.org/content/18/24/6580.full-text.pdf> |
| Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. *Immunity.* 2013;39:1-10. | [www.cell.com/action/showPdf?pii=S1074-7613%2813%2900296-3](https://www.cell.com/action/showPdf?pii=S1074-7613%2813%2900296-3) |
| Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. *Nat Rev Immunol.* 2013;13:227-242. | [www.ncbi.nlm.nih.gov/pmc/articles/PMC3786574/pdf/nihms-482692.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786574/pdf/nihms-482692.pdf) |
| Daniels GA, Guerrera AD, Katz D, Viets-Upchurch J. Challenge of immune-mediated adverse reactions in the emergency department. *Emerg Med J.* 2019;36:369-377. | <https://emj.bmj.com/content/emermed/36/6/369.full.pdf> |
| Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. *Eur J Immunol*. 2017;47:765-779. | <https://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.201646875> |
| Khunger M, Hernandez AV, Pasupuleti V, et al. Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors: A systematic review and meta-analysis. *JCO Precis Oncol.* 2017;1:1-15. | <https://ascopubs.org/doi/pdfdirect/10.1200/PO.16.00030> |
| Pardoll DM*.* The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer.* 2012;12:252-264. | [www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023/pdf/nihms-779907.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023/pdf/nihms-779907.pdf) |
| Røsland GV, Engelsen AST. Novel points of attack for targeted cancer therapy. *Basic Clin Pharmacol Toxicol*. 2015;116:9-18. | <https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.12313> |
| Scaltriti M, Baselga J.The epidermal growth factor receptor pathway: A model for targeted therapy. *Clin Cancer Res.* 2006;12:5268-5272. | [https://clincancerres.aacrjournals.org/content/12/18/5268.full-text.pdf#](https://clincancerres.aacrjournals.org/content/12/18/5268.full-text.pdf) |
| Singh PP, Sharma PK, Krishnan G, Lockhart AC. Immune checkpoints and immunotherapy for colorectal cancer. *Gastroenterol Rep(Oxf).* 2015;3:289-297. | <https://www.ncbi.nlm.nih.gov/pubmed/26510455> |
| Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. *Nat Rev Cancer.* 2011;11:805-812. | [www.ncbi.nlm.nih.gov/pmc/articles/PMC3426440/pdf/nihms387517.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426440/pdf/nihms387517.pdf) |
| Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. *Cancer Res.* 2015;75:2139-2145. | <http://cancerres.aacrjournals.org/content/canres/75/11/2139.full.pdf> |

**Biomarkers**

|  |  |
| --- | --- |
| Resource | Address |
| Abida W, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. *JAMA Oncol.* 2019;5:471-478. | <https://www.ncbi.nlm.nih.gov/pubmed/30589920> |
| Appierto V, et al. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case. *Semin Cancer Biol*. 2017;44:106-116. | <https://www.ncbi.nlm.nih.gov/pubmed/28442298> |
| Arkenau HT. PD-L1 in cancer: ESMO biomarker factsheet. ESMO OncologyPro. Updated December 7, 2017. | <https://oncologypro.esmo.org/education-library/factsheets-on-biomarkers/pd-l1-in-cancer> |
| Wu J, et al. Co-administration of novel anti-sMIC antibody increases anti-CTLA-4 therapeutic response in TRAMP/MIC mice (O22). Presented at the Society of Immunotherapy 32nd Annual Meeting; November 10, 2017; National Harbor, MD.. | <http://blog.sitcancer.org/2017/11/sitc-2017-scientific-highlights-nov-10.html> |
| Badalamenti G, et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone. *Cell Immunol*. 2019 343:103753 | <https://pubmed.ncbi.nlm.nih.gov/29395859/> |
| Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med.* 2015;373:1627-1639. | <https://www.ncbi.nlm.nih.gov/pubmed/26412456> |
| Brahmer J, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med.* 2015;373:123-135. | <https://www.ncbi.nlm.nih.gov/pubmed/26028407> |
| Bigras G, et al. Small biopsies misclassify up to 35% of PD-L1 assessments in advanced lung non-small cell lung carcinomas. *Appl Immunohistochem Mol Morphol*. 2018;26:701-708. | <https://www.ncbi.nlm.nih.gov/pubmed/30095468> |
| Brooks JD. Translational genomics: The challenge of developing cancer biomarkers. *Genome Res*. 2012;22:183-187. | <https://genome.cshlp.org/content/22/2/183.full.pdf> |
| Burrell RA, et al. The causes and consequences of genetic heterogeneity in cancer evolution. *Nature*. 2013;501:338-345. | <https://www.ncbi.nlm.nih.gov/pubmed/24048066> |
| Butterfield LH. The society for immunotherapy of cancer biomarkers task force recommendations review. *Semin Cancer Biol*. 2018;52:12-15. | <https://www.ncbi.nlm.nih.gov/pubmed/28943324> |
| Cabel L, et al. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. *Nat Rev Ciln Oncol*. 2018;15:639-650. | <https://www.ncbi.nlm.nih.gov/pubmed/30050094> |
| Canadian Cancer Trials Group. Canadian study is the first randomized trial to demonstrate immunotherapy benefit in patients with colorectal cancer. Presented at the 2019 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 19, 2017; Kingston, Ontario. Accessed August 23, 2020. | <https://www.ctg.queensu.ca/cctg_media_releases/canadian-study-first-randomized-trial-demonstrate-immunotherapy-benefit-patients> |
| Chan TA, et al. Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic. *Ann Oncol.* 2019;30:44-56. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336005/pdf/mdy495.pdf> |
| Chen EX, et al. CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC). *J Clin Oncol*. 2019;37(4 suppl):481. | <https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4_suppl.481> |
| Dudley JC, et al. Microsatellite instability as a biomarker for PD-1 blockade. *Clin Cancer Res.* 2016;22:813-820. | <https://clincancerres.aacrjournals.org/content/clincanres/22/4/813.full.pdf> |
| Duffy MJ, et al. Validation of new cancer biomarkers: A position statement from the European group on tumor markers. *Clin Chem.* 2015;61:809-820. | <https://academic.oup.com/clinchem/article/61/6/809/5611472> |
| Efremova M, et al. Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. *Front Immunol*. 2017;8:1679. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712389/pdf/fimmu-08-01679.pdf |
| Galon J, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. *J Pathol*. 2014;232:199-209. | <https://onlinelibrary.wiley.com/doi/epdf/10.1002/path.4287> |
| Gerlinger M, et al. Intratumour heterogeneity in urologic cancers: From molecular evidence to clinical implications. *Eur Urol*. 2015;67:729-737. | <https://www.ncbi.nlm.nih.gov/pubmed/24836153> |
| Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. *J Immunother Cancer*. 2018;6:8. | <https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-018-0316-z> |
| Gradecki SE, et al. Concordance of PD-L1 expression between core biopsy and resection specimens of non-small cell lung cancer. *Am J Surg Pathol*. 2018;42:1090-1094. | <https://www.ncbi.nlm.nih.gov/pubmed/29794870> |
| Granier C, De Guillebon E, Blanc C, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. *ESMO Open*. 2017;2:e000213. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518304/pdf/esmoopen-2017-000213.pdf> |
| Hellmann MD, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. *Cancer Cell.* 2018;33:853-861. | <https://www.ncbi.nlm.nih.gov/pubmed/29731394> |
| Herbst RS, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. *Lancet.* 2016;387:1540-1550. | <https://www.ncbi.nlm.nih.gov/pubmed/26712084> |
| Hirsch FR, et al. PD-L1 Immunohistochemistry assays for lung cancer: Results from phase 1 of the blueprint PD-L1 IHC assay comparison project. *J Thorac Oncol*. 2017;12:208-222. | <https://www.ncbi.nlm.nih.gov/pubmed/27913228> |
| Ilié M, Hofman P. Pros: Can tissue biopsy be replaced by liquid biopsy?. *Transl Lung Cancer Res*. 2016;5:420-423. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009092/pdf/tlcr-05-04-420.pdf> |
| Kluger HM, et al. PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors. *Clin Cancer Res*. 2017;23:4270-4279. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540774/pdf/nihms855367.pdf> |
| Khunger M, et al. Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors: A systematic review and meta-analysis. *JCO Precis Oncol.* 2017;1:1-15 | <https://ascopubs.org/doi/pdfdirect/10.1200/PO.16.00030> |
| Lawrence MS, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature.* 2013;499:214-218. | <https://www.ncbi.nlm.nih.gov/pubmed/23770567> |
| Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science.* 2017;357:409-413. | <https://science.sciencemag.org/content/sci/357/6349/409.full.pdf> |
| Li J, et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. *Immunity.* 2018;49:178-193.e7. | <https://www.ncbi.nlm.nih.gov/pubmed/29958801> |
| Marín-García, J. Chapter 19 - The aging heart: A post-genomic appraisal. In: *Post-Genomic Cardiology. 2nd ed.* Cambridge, MA; Elsevier Academic Press; 2014:641-682. | <https://www.sciencedirect.com/science/article/pii/B9780124045996000196> |
| Masucci GV, et al. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. *J Immunother Cancer*. 2016;4:76. | <https://jitc.biomedcentral.com/articles/10.1186/s40425-016-0178-1> |
| McLaughlin J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. *JAMA Oncol.* 2016;2:46-54. | <https://www.ncbi.nlm.nih.gov/pubmed/26562159> |
| Melero I, et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. *Nat Rev Cancer*. 2015;15:457-472. | <https://www.ncbi.nlm.nih.gov/pubmed/26205340> |
| Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer. *Front Oncol.* 2019:9:396. | [www.ncbi.nlm.nih.gov/pmc/articles/PMC6527887/pdf/fonc-09-00396.pdf](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527887/pdf/fonc-09-00396.pdf) |
| Pandey MR, Ernstoff MS. Mechanism of resistance to immune checkpoint inhibitors. *Cancer Drug Resist*. 2019;2:178-188. | <https://oaepublishstorage.blob.core.windows.net/460a0841-5910-4850-9449-c77783b35b7b/3081.pdf> |
| Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. *Mol Cancer Ther*. 2015;14:847-856. | <https://mct.aacrjournals.org/content/molcanther/14/4/847.full.pdf> |
| Peters S, et al. Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. *Cancer Res.* 2019;79(13 suppl):CT074 | [https://cancerres.aacrjournals.org/content/79/13\_Supplement/CT074](https://cancerres.aacrjournals.org/content/79/13_Supplement/CT074.short) |
| Pinato DJ et al. Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy. *Oncoimmunology.* 2016;5:e1213934. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048760/pdf/koni-05-09-1213934.pdf> |
| Rittmeyer A, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. *Lancet.* 2017;389:255-265. | <https://www.ncbi.nlm.nih.gov/pubmed/27979383> |
| Rojkó L, et al. Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. *J Cancer Res Clin Oncol*. 2018;144:1219-1226. | <https://www.ncbi.nlm.nih.gov/pubmed/29675791> |
| Samstein RM, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet*. 2019;51:202-206. | <https://www.ncbi.nlm.nih.gov/pubmed/30643254> |
| Shirazi M et al. Therapy implications of DNA mismatch repair deficiency, microsatellite instability, and tumor mutation burden. *Advances in Molecular Pathology.* 2018;1:193-208. | <https://www.sciencedirect.com/science/article/pii/S2589408018300218> |
| Vilain RE, et al. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. *Clin Cancer Res*. 2017;23:5024-5033. | <https://clincancerres.aacrjournals.org/content/clincanres/23/17/5024.full.pdf> |
| Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. *J Hematol Oncol*. 2019;12:54. | <https://jhoonline.biomedcentral.com/track/pdf/10.1186/s13045-019-0738-1> |

**Immune-related adverse events (irAEs) and their management**

|  |  |
| --- | --- |
| Resource | Address |
| Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. *J Immunother.* 2005;28:593-598. | [www.ncbi.nlm.nih.gov/pmc/articles/PMC2154350/pdf/nihms35758.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2154350/pdf/nihms35758.pdf) |
| Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2016;101:364-389. | <https://academic.oup.com/jcem/article/101/2/364/2810222> |
| Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol.* 2018;36:1714-1768. | <https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2017.77.6385> |
| Buder-Bakhaya K, Benesova K, Schulz C, et al. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. *Cancer Immunol Immunother.* 2018;67:175-182. | <https://www.ncbi.nlm.nih.gov/pubmed/29018908> |
| Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. *Ann Rheum Dis.* 2017;76:43-50. | <https://ard.bmj.com/content/annrheumdis/76/1/43.full.pdf> |
| Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. *Ann Oncol.* 2016;27:559-574. | <https://www.annalsofoncology.org/article/S0923-7534(19)35750-3/pdf> |
| Chang J, Tran J, Kamel D, Basu A. Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer. *BMJ Case Rep.* 2019;12:e228135. | <https://pubmed.ncbi.nlm.nih.gov/30850565/> |
| Chuzi S, Tavora F, Cruz M, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. *Cancer Manag Res.* 2017;9:207-213. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476791/pdf/cmar-9-207.pdf> |
| Dalakas MC. Neurological complications of immune checkpoint inhibitors: What happens when you 'take the brakes off' the immune system. *Ther Adv Neurol Disord*. 2018;11:1756286418799864. | [www.ncbi.nlm.nih.gov/pmc/articles/PMC6144585/pdf/10.1177\_1756286418799864.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144585/pdf/10.1177_1756286418799864.pdf) |
| Forde PM, Rock K, Wilson G, O’Byrne KJ. Ipilimumab-induced immune-related renal failure — a case report. *Anticancer Res.* 2012;32:4607-4608. | <http://ar.iiarjournals.org/content/32/10/4607.full.pdf> |
| Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. *JAMA Oncol*. 2016;2:1346-1353. | <https://www.ncbi.nlm.nih.gov/pubmed/27367787> |
| Ganantra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. *Oncologist*. 2018;23:879-886. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156176/pdf/onco12588.pdf> |
| Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: Symptoms, endoscopic features, histology and response to management. *ESMO Open*. 2018;3:e000278. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786923/pdf/esmoopen-2017-000278.pdf> |
| Godwin JL, Jaggi S, Sirisena I, et al. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. *J Immunother Cancer.* 2017;5:40. | <https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-017-0245-2> |
| Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: Algorithms for management. *Am Soc Clin Oncol Educ Book*. 2018;38:13-19. | <https://ascopubs.org/doi/pdfdirect/10.1200/EDBK_100013> |
| Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: Colitis associated with anti-CTLA-4 therapy. *Aliment Pharmacol Ther*. 2015;42:406-417. | <https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.13281> |
| Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2017;28(suppl 4):iv119-iv142. | <https://www.annalsofoncology.org/article/S0923-7534(19)42153-4/pdf> |
| Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med.* 2010;363:711-723. | <https://www.nejm.org/doi/pdf/10.1056/NEJMoa1003466> |
| Hottinger AF. Neurologic complications of immune checkpoint inhibitors. *Curr Opin Neurol*. 2016;29:806-812. | <https://www.ncbi.nlm.nih.gov/pubmed/27653290> |
| Hryniewicki AT, Wang C, Shatsky RA, Coyne CJ. Management of immune checkpoint inhibitor toxicities: A review and clinical guideline for emergency physicians. *J Emerg Med*. 2018;55:489-502. | <https://www.ncbi.nlm.nih.gov/pubmed/30120013> |
| Johnson DB, Chandra S, Sosman JA. Immune checkpoint inhibitor toxicity in 2018. *JAMA.* 2018;320:1702-1703. | <https://www.ncbi.nlm.nih.gov/pubmed/30286224> |
| Khan Z, Hammer C, Guardino E, et al. Mechanisms of immune-related adverse events associated with immune checkpoint blockade: Using germline genetics to develop a personalized approach. *Genome Med.* 2019:11:39. | <https://genomemedicine.biomedcentral.com/track/pdf/10.1186/s13073-019-0652-8> |
| Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials. *Chest*. 2017;152:271-281. | <https://www.ncbi.nlm.nih.gov/pubmed/28499515> |
| Koelzer VH, Buser T, Willi N, et al. Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. *J Immunother Cancer.* 2016;4:47. | <https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-016-0151-z> |
| Kottschade L, Brys A, Peikert T, et al. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. *Melanoma Res.* 2016;26:469-480. | <https://www.ncbi.nlm.nih.gov/pubmed/27306502> |
| Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. *Front Pharmacol.* 2017;8:49. | <https://core.ac.uk/download/pdf/82875952.pdf> |
| Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. *Ann Transl Med.* 2016;4:272. | <http://atm.amegroups.com/article/view/11068/11645> |
| Mellati M, Eaton KD, Brooks-Worrell BM, et al. Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing type 1 diabetes. *Diabetes Care.* 2015;38:e137-e138. | <https://care.diabetesjournals.org/content/diacare/38/9/e137.full.pdf> |
| Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. *Ann Oncol*. 2015;26:2375-2391. | <https://www.ncbi.nlm.nih.gov/pubmed/26371282> |
| NIH. National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0). Published November 27, 2017. | <https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf> |
| National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Management of Immunotherapy-Related Toxicities (version 1.2020).Published December 16, 2019. | [www.nccn.org/professionals/physician\_gls/pdf/immunotherapy.pdf](http://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf) |
| Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy. *N Engl J Med.* 2015;373:288-290. | [www.ncbi.nlm.nih.gov/pmc/articles/PMC4539956/pdf/nihms711760.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539956/pdf/nihms711760.pdf) |
| O’Kane GM, et al. Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer. *Oncologist.* 2017;22:70-80 | <https://theoncologist.onlinelibrary.wiley.com/doi/epdf/10.1634/theoncologist.2016-0164> |
| Pallin DJ, Baugh CW, Postow MA, et al. Immune-related adverse events in cancer patients. *Acad Emerg Med.* 2018;25:819-827. | <https://onlinelibrary.wiley.com/doi/epdf/10.1111/acem.13443> |
| Pathria M, Mundi J, Trufant J. A case of Stevens–Johnson syndrome in a patient on ipilimumab. *Int J Case Rep Imag.* 2016;7:300-302. | [www.ijcasereportsandimages.com/archive/2016/005-2016-ijcri/CR-10639-05-2016-pathria/ijcri-1063905201639-pathria.pdf](http://www.ijcasereportsandimages.com/archive/2016/005-2016-ijcri/CR-10639-05-2016-pathria/ijcri-1063905201639-pathria.pdf) |
| Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med.* 2018;378:158-168. | <https://www.nejm.org/doi/10.1056/NEJMra1703481> |
| Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. *J Immunother Cancer*. 2017;5:95. | <https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-017-0300-z> |
| Roberts K, Culleton V, Lwin Z, et al. Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. *Asia Pac J Clin Oncol.* 2017;13:277-288. | <https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.12698> |
| Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy. *Am J Clin Dermatol*. 2018;19:345-361. | <https://www.ncbi.nlm.nih.gov/pubmed/29256113> |
| Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature. *Ann Oncol.* 2017;28:377-385. | <https://www.ncbi.nlm.nih.gov/pubmed/28426103> |
| Stroud CR, Hegde A, Cherry C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. *J Oncol Pharm Pract*. 2019;25:551-557. | <https://www.ncbi.nlm.nih.gov/pubmed/29207939> |
| Suzman DL, et al. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. *Liver Int.* 2018;38:976-987. | <https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.13746> |
| Sznol M, Ferrucci PF, Hogg D, et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. *J Clin Oncol.* 2017;35:3815-3822. | <https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2016.72.1167> |
| Teply BA, Lipson EJ. Identification and management of toxicities from immune checkpoint-blocking drugs. *Oncology* *(Williston Park).* 2014;28(suppl 3):30-38. | <https://www.ncbi.nlm.nih.gov/pubmed/25384885> |
| Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med.* 2012;366:2443-2454. | <https://www.nejm.org/doi/pdf/10.1056/NEJMoa1200690> |
| Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma. *Cancer.* 2013;119:1675-1682. | <https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.27969> |
| Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. *J Clin Oncol.* 2012;30:2691-2697. | <http://ascopubs.org/doi/full/10.1200/jco.2012.41.6750> |
| Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. *Oncologist.* 2016;21:1230-1240. | <https://theoncologist.onlinelibrary.wiley.com/doi/epdf/10.1634/theoncologist.2016-0055> |
| Zhang X, Ran Y, Wang K, et al. Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: A meta-analysis. *Drug Des Devel Ther*. 2016;10:3153-3161. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047728/pdf/dddt-10-3153.pdf> |

**Shared Decision-Making**

|  |  |
| --- | --- |
| Resource | Address |
| Agency for Healthcare Research and Quality (AHRQ): SHARE Approach Workshop. Reviewed September 2016. | [www.ahrq.gov/health-literacy/curriculum-tools/shareddecisionmaking/workshop/index.html](https://www.ahrq.gov/health-literacy/curriculum-tools/shareddecisionmaking/workshop/index.html) |
| Agency for Healthcare Research and Quality (AHRQ): SHARE Approach Curriculum Tools. Reviewed December 2018.  *Highlights:*  Tool 2—Conversation starters  Tool 6—Teach-back technique  Tool 8—Implementing shared decision-making (SDM) | [www.ahrq.gov/professionals/education/curriculum-tools/shareddecisionmaking/tools/index.html](https://www.ahrq.gov/professionals/education/curriculum-tools/shareddecisionmaking/tools/index.html) |
| Barry MJ, Edgman-Levitan S, Sepucha K. Shared decision-making: Staying focused on the ultimate goal. *NEJM Catal.* Published September 6, 2018. | <https://catalyst.nejm.org/doi/full/10.1056/CAT.18.0097> |
| Fisher KA, Tan ASL, Matlock DD, et al. Keeping the patient in the center: Common challenges in the practice of shared decision making. *Patient Educ Couns.* 2018;101:2195-2201. | <https://www.ncbi.nlm.nih.gov/pubmed/30144968> |
| Hess EP, Grudzen CR, Thomson R, et al. Shared decision-making in the emergency department: Respecting patient autonomy when seconds count. *Acad Emerg Med.* 2015;22:856-864. | <https://onlinelibrary.wiley.com/doi/epdf/10.1111/acem.12703> |
| Kunneman M, Branda ME, Hargraves I, et al. Fostering choice awareness for shared decision making: A secondary analysis of video-recorded clinical encounters. *Mayo Clin Proc Innov Qual Outcomes*. 2018;2:60-68. | <https://mcpiqojournal.org/article/S2542-4548(17)30131-5/pdf> |
| Légaré F, Thomson-Leduc P. Twelve myths about shared decision making. *Patient Educ Couns.* 2014;96:281-286. | <https://reader.elsevier.com/reader/sd/pii/S0738399114002699?token=95260B48F273C0F4FE72984FAB79EABA9138B12BEA0017BE91CA59F7EA1F64AAAABF7A496F5E28425B43E243BCE1D452>  <https://reader.elsevier.com/reader/sd/pii/S0738399114002699> |
| Marco CA, Kraus C. ACEP’s choosing wisely recommendations stress importance of shared decision making in emergency medicine. *ACEP Now.* May 9, 2014. | [www.acepnow.com/article/aceps-choosing-wisely-recommendations-stress-importance-shared-decision-making-emergency-medicine/?singlepage=1](https://www.acepnow.com/article/aceps-choosing-wisely-recommendations-stress-importance-shared-decision-making-emergency-medicine/?singlepage=1) |
| Melnick E, Hess E. How shared decision making in the emergency department can improve value. *Health Affairs Blog.* February 7, 2017. | [www.healthaffairs.org/do/10.1377/hblog20170207.058610/full/](https://www.healthaffairs.org/do/10.1377/hblog20170207.058610/full/) |
| Tariman J. Welcome to the Era of Shared Decision-Making. *ASH Clinical News. July 1,* 2016. | [www.ashclinicalnews.org/perspectives/advanced-practice-voices/welcome-to-the-era-of-shared-decision-making/](https://www.ashclinicalnews.org/perspectives/advanced-practice-voices/welcome-to-the-era-of-shared-decision-making/) |
| Vahdat S, Hamzehgardeshi L, Hessam S, Hamzehgardeshi Z. Patient involvement in health care decision making: A review. *Iran Red Cres Med J.* 2014;16:e12454. | [www.ncbi.nlm.nih.gov/pmc/articles/PMC3964421/pdf/ircmj-16-12454.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964421/pdf/ircmj-16-12454.pdf) |

**Decision Aids**

|  |  |
| --- | --- |
| Resource | Address |
| Stacy D, Légaré F, Lewis K, et al. Decision aids to help people who are facing health treatment or screening decisions (review). *Cochrane Database Syst Rev. April 12,* 2017. | [www.cochrane.org/CD001431/COMMUN\_decision-aids-help-people-who-are-facing-health-treatment-or-screening-decisions](https://www.cochrane.org/CD001431/COMMUN_decision-aids-help-people-who-are-facing-health-treatment-or-screening-decisions) |
| Patient Decision Aids. The Ottawa Hospital Research Institute | <https://decisionaid.ohri.ca/index.html> |